Volume 2 Supplement 2

Abstracts of the 1st Immunotherapy of Cancer Conference (ITOC1)

Meeting abstracts

Edited by Heinz Zwierzina and Volkmar Nuesslar

Publication of this supplement was funded by the Biotherapy Development Association, a non-profit organisation. The Supplement Editors declare that they have no competing interests.

1st Immunotherapy of Cancer Conference (ITOC1). Go to conference site.

Munich, Germany12-14 March 2014

Content type: Invited speaker presentation

S2. Therapeutic strategies based on overcoming immune resistance mechanisms within the melanoma tumour microenvironment

Authors: T Gajewski

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):I1

Published on: 12 March 2014
- View Full Text
- View PDF
Content type: Invited speaker presentation

S5. Proffered paper: Maintenance therapy of metastatic colorectal carcinoma with the TLR-9 agonist MGN1703: clinical and immunological predictive pretreatment factors of activity in the IMPACT trial

Authors: H Schmoll, BW Wittig, DA Arnold, JRK Riera-Knorrenschild, DN Nietsche, HK Kroening, FM Mayer, JA Andel, RZ Ziebermayr and WS Scheithauer

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):I2

Published on: 12 March 2014
- View Full Text
- View PDF
Content type: Invited speaker presentation

S6. Proffered paper: Anti-tumour immunomodulatory activity of heat shock protein Hsp70 in therapy of malignant brain tumours: preclinical and clinical data

Authors: M Shevtsov, A Kim, W Khachatryan, A Pozdnyakov, I Romanova, I Guzhova and B Margulis

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):I3

Published on: 12 March 2014
- View Full Text
- View PDF
Content type: Invited speaker presentation

S7. KEYNOTE LECTURE: Immunobiological properties of the human cancer stem cells

Authors: C Maccalli, EZ Elisabetta Zambon, FC Filippo Capocefalo and GP Giorgio Parmiani

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):I4

Published on: 12 March 2014
- View Full Text
- View PDF
Content type: Invited speaker presentation

S9. Proffered paper: Identification of novel immune checkpoints as targets for cancer immunotherapy

Authors: G Cojocaru, G Rotman, O Levy, A Toporik, L Dassa, I Vaknin, S Sameah-Greenwald, I Barbiro, E Neria and Z Levine

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):I5

Published on: 12 March 2014
- View Full Text
- View PDF
Content type: Invited speaker presentation

S35. Investigating the ICOS/ICOSL pathway as a target for combination therapy with anti-CTLA-4

Authors: P Sharma

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):I6

Published on: 12 March 2014
- View Full Text
- View PDF
Content type: Invited speaker presentation

S38. Many reasons for combining immunotherapy with chemotherapy to enhance anti tumour response

Authors: A Dalgleish, D Fowler, A Gravett, R Allen and W Liu

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):I7

Published on: 12 March 2014
- View Full Text
- View PDF
Content type: Invited speaker presentation

S41. Novel CEA-targeted IL2 variant immunocytokine for immunotherapy of cancer

Authors: C Klein

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):I8

Published on: 12 March 2014
- View Full Text
- View PDF
Content type: Invited speaker presentation

S43. Dendritic cell vaccination combined with CTLA4 blockade

Authors: K Thielemans and B Neyns

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):I9

Published on: 12 March 2014
- View Full Text
- View PDF
Content type: Invited speaker presentation

S47. Tumour infiltrating lymphocytes - a predictive marker?

Authors: J Galon

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):I10

Published on: 12 March 2014
- View Full Text
- View PDF
Content type: Invited speaker presentation

S48. Biomarker development for ipilimumab and prostate GVAX treatment

Authors: T de Gruijl, S Santegoets, A Stam, S Lougheed, K Jooss, N Sacks, T Harding, K Hege, W Gerritsen and A van den Eertwegh

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):I11

Published on: 12 March 2014
- View Full Text
- View PDF
Content type: Invited speaker presentation

S50. Proffered paper: Complex tumour microenvironment screening platform captures biological responses of cancer therapeutics

Authors: H Layman, J Melrose, W Tang, N Brown, D Nguyen, A Melton, M Polokoff, E Berg and A O'Mahony

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):I12

Published on: 12 March 2014
- View Full Text
- View PDF
Content type: Invited speaker presentation

S75. KEYNOTE LECTURE: Basic concept for the understanding of cancer mediated immune rejection

Authors: F Marincola and E Wang

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):I13

Published on: 12 March 2014
- View Full Text
- View PDF
Content type: Invited speaker presentation

S76. Adoptive cell therapy of melanoma with autologous tumour infiltrating lymphocytes

Authors: I Svane, R Andersen and M Donia

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):I14

Published on: 12 March 2014
- View Full Text
- View PDF
Content type: Invited speaker presentation

S77. Proffered paper: In vitro induced response patterns of antileukemic T-cells – characterization by combination of functional assays, spectratyping and next generation sequencing

Authors: S Reuther, P Krell, FR Schuster, C Grabrucker, A Liepert, T Kroell, HJ Kolb, A Borkhardt, R Buhmann and H Schmetzer

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):I15

Published on: 12 March 2014
- View Full Text
- View PDF
Content type: Invited speaker presentation

S78. Proffered paper: High-affinity CD20-specific TCRs suitable for adoptive immunotherapy can be readily isolated from the allo-repertoire using reverse immunology

Authors: L Jahn, P Hombrink, C Hassan, MGD Kester, MP Schoonakker, JHF Falkenburg, P van Veelen and MHM Heemskerk

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):I16

Published on: 12 March 2014
- View Full Text
- View PDF
Content type: Invited speaker presentation

S79. CAR strategies in solid tumours

Authors: C Rossig

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):I17

Published on: 12 March 2014
- View Full Text
- View PDF
Content type: Invited speaker presentation

S80. Prolongation of T cell response by OX40 co-signalling CARS

Authors: H Abken

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):I18

Published on: 12 March 2014
- View Full Text
- View PDF
Content type: Invited speaker presentation

S81. Proffered paper: A new PD1-CD28 chimeric receptor overcomes PD-1-mediated immunosuppression in adoptive T cell therapy

Authors: S Grassmann, P Peters, Y Zeng, J Schmollinger, S Endres and S Kobold

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):I19

Published on: 12 March 2014
- View Full Text
- View PDF
Content type: Invited speaker presentation

S82. Proffered paper: In-vivo testing of PSMA-targeted T-cell immunotherapy for prostate cancer

Authors: Z Liu, SB Papa, J Morris and J Maher

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):I20

Published on: 12 March 2014
- View Full Text
- View PDF

Journal for ImmunoTherapy of Cancer

Abstracts of the 1st Immunotherapy of Cancer Conference (ITOC1)

Meeting abstracts

S2. Therapeutic strategies based on overcoming immune resistance mechanisms within the melanoma tumour microenvironment

S5. Proffered paper: Maintenance therapy of metastatic colorectal carcinoma with the TLR-9 agonist MGN1703: clinical and immunological predictive pretreatment factors of activity in the IMPACT trial

S6. Proffered paper: Anti-tumour immunomodulatory activity of heat shock protein Hsp70 in therapy of malignant brain tumours: preclinical and clinical data

S7. KEYNOTE LECTURE: Immunobiological properties of the human cancer stem cells

S9. Proffered paper: Identification of novel immune checkpoints as targets for cancer immunotherapy

S35. Investigating the ICOS/ICOSL pathway as a target for combination therapy with anti-CTLA-4

S38. Many reasons for combining immunotherapy with chemotherapy to enhance anti tumour response

S41. Novel CEA-targeted IL2 variant immunocytokine for immunotherapy of cancer

S43. Dendritic cell vaccination combined with CTLA4 blockade

S47. Tumour infiltrating lymphocytes - a predictive marker?

S48. Biomarker development for ipilimumab and prostate GVAX treatment

S50. Proffered paper: Complex tumour microenvironment screening platform captures biological responses of cancer therapeutics

S75. KEYNOTE LECTURE: Basic concept for the understanding of cancer mediated immune rejection

S76. Adoptive cell therapy of melanoma with autologous tumour infiltrating lymphocytes

S77. Proffered paper: In vitro induced response patterns of antileukemic T-cells – characterization by combination of functional assays, spectratyping and next generation sequencing

S78. Proffered paper: High-affinity CD20-specific TCRs suitable for adoptive immunotherapy can be readily isolated from the allo-repertoire using reverse immunology

S79. CAR strategies in solid tumours

S80. Prolongation of T cell response by OX40 co-signalling CARS

S81. Proffered paper: A new PD1-CD28 chimeric receptor overcomes PD-1-mediated immunosuppression in adoptive T cell therapy

S82. Proffered paper: In-vivo testing of PSMA-targeted T-cell immunotherapy for prostate cancer

Official journal of

Follow

2017 Journal Metrics

Journal for ImmunoTherapy of Cancer

Contact us